Gilead Sciences Inc. (GILD): 47th Annual Global Healthcare Conference Key Takeaways

Goldman Sachs provides takeaways from the 47th Annual Global Healthcare Conference, highlighting strong performance for Yeztugo, positive HIV pipeline developments, and strategic adjustments to oncology programs.

Key Takeaways

• 1.Gilead continues to see strong performance in the Yeztugo launch, with key metrics tracking at or above expectations, leading to a FY26 revenue guidance raise.
• 2.Gilead reported positive Ph3 results for its ISL/LEN HIV treatment, with plans to target a potential 2027 US launch focused on switch patients.
• 3.The company is discontinuing the Ph3 (EVOKE-03) study of Trodelvy in combination with Keytruda for mNSCLC after failing to reach statistical significance in overall survival.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial